Trending

cost-effectiveness

NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has

X

NICE says ‘no’ to Pfizer’s Vyndaqel for rare heart condition

https://pharmaphorum.com/news/nice-says-no-to-pfizers-vyndaqel-for-rare-heart-condition/

NICE unveils five year plan promising faster access to medicines

NICE unveils five year plan promising faster access to medicines

NICE has included proposals to speed up evaluations and focus on new technology such as digital health in

X

NICE unveils five year plan promising faster access to medicines

https://pharmaphorum.com/news/nice-unveils-five-year-plan-promising-faster-access-to-medicines/

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide

X

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

https://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/

NICE rejects BMS’ Zeposia MS pill in provisional guidance

NICE rejects BMS’ Zeposia MS pill in provisional guidance

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing

X

NICE rejects BMS’ Zeposia MS pill in provisional guidance

https://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/

After two decades, NICE begins consultation on drug assessment methods

After two decades, NICE begins consultation on drug assessment methods

The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how

X

After two decades, NICE begins consultation on drug assessment methods

https://pharmaphorum.com/news/nice-begins-consultation-on-cost-effectiveness-methods/

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance. The cost-effectiveness body said

X

NICE rejects Sanofi’s Cablivi for rare blood disorder TTP

https://pharmaphorum.com/news/nice-rejects-sanofis-cablivi-for-rare-blood-disorder-ttp/

Study sets benchmark for cost of repurposed coronavirus drugs

Study sets benchmark for cost of repurposed coronavirus drugs

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for

X

Study sets benchmark for cost of repurposed coronavirus drugs

https://pharmaphorum.com/news/study-sets-benchmark-for-cost-of-repurposed-coronavirus-drugs/

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people

X

NICE backs NHS funding for Roche’s Kadcyla in early breast cancer use

https://pharmaphorum.com/market-access-2/nice-backs-nhs-funding-for-roches-kadcyla-in-early-breast-cancer-use/

NICE rejects Roche’s Polivy combination in advanced lymphoma

NICE rejects Roche’s Polivy combination in advanced lymphoma

England’s NHS should not fund Roche’s Polivy (polatuzumab vedotin) in combination with rituximab and bendamustine for adults with

X

NICE rejects Roche’s Polivy combination in advanced lymphoma

https://pharmaphorum.com/news/nice-rejects-roches-polivy/

1 2 3 4 5 >»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com